Boehringer buys ViraTherapeutics
Boehringer Ingelheim has exercised an option to acquire all shares of oncolytic virus company ViraTherapeutics. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/boehringer_buys_viratherapeutics_1252039Boehringer Ingelheim has exercised an option to acquire all shares of oncolytic virus company ViraTherapeutics. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/boehringer_buys_viratherapeutics_1252039The US Food and Drug Administration has rejected Valeant group Ortho Dermatologics’ plaque psoriasis therapy Duobrii. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/us_regulators_reject_valeants_duobrii_1240725NHS funding has been approved for the drug's use as a treatment for opioid-induced constipation - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/nice_backs_shionogis_rizmoic_1352229This year's competition welcomed a fantastic spread of companies as well as a higher number of entrants - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/pharmatimes_unveils_winners_of_msea_2019_1319263Trial results and cost-effectiveness are too uncertain for NHS use, the Institute said - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/nice_turns_down_novartis_adakveo_1358458The approval marks a "significant milestone in Ebola prepardness and prevention" - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/us_approves_mercks_ebola_vaccine_1320832GW Pharmaceuticals and its US subsidiary Greenwich Biosciences have completed the rolling submission of Epidiolex as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome, two difficult-to-treat forms of
by Selina McKee
www.pharmatimes.com/news/gw_completes_epidiolex_submission_1209905The drug's label now includes a dosing regimen specifically to treat hyperkalaemia in patients with end-stage renal disease on stable hemodialysis - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/us_clears_label_update_for_az_lokelma_1339089The National Institute for Health and Care Excellence and the Ethical Medicines Industry Group (EMIG) are working together to increase understanding of the services the Institute offers the life sciences industry. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/nice_links_with_emig_1276689Merck is investing $125 million in Moderna under a new deal that expands the firms’ 2016 partnership to develop messenger RNA cancer vaccines. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/merck_invests_in_moderna_1234371